Ovid Therapeutics Q1 net loss $10.2M; OV329 data on track for Q3 2025

Ovid Therapeutics Inc.

Cash and equivalents $43.0M at March 31, 2025; expected to fund operations into 2H 2026.
Topline Phase 1 biomarker and safety data for OV329 (GABA-AT inhibitor) expected in Q3 2025.
OV350 KCC2 direct activator dosed in Phase 1 in Q1 2025; safety/tolerability results expected Q4 2025.
Q1 net loss $10.2M ($0.14/sh) vs $11.7M ($0.17/sh) a year ago; total op expenses down 28% to $12.7M.
Oral KCC2 candidate OV4071 on track to initiate proof-of-concept study in H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.